Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1451651 | 0.80 | LMNA (0.46) | ELANEKMT2AMEN1KDM4ELMNA | |
| SCHEMBL16955344 | 0.77 | LMNA (0.41) | CA2KMT2AMEN1KDM4ELMNA | |
| SCHEMBL9817182 | 0.77 | ELANE (0.49) | ELANEALOX15CA2HTR1DHTR1B | |
| SCHEMBL6201296 | 0.75 | ELANE (0.60) | ELANEALOX15CA2HTR1DHTR1B | |
| SCHEMBL21795326 | 0.75 | ELANE (0.79) | ELANEALOX15CA2HTR1DHTR1B | |
| SCHEMBL16950659 | 0.73 | BACE1 (0.43) | KMT2AMEN1KDM4ELMNATTR | |
| SCHEMBL809187 | 0.73 | ELANE (0.53) | ELANEALOX15CA2KMT2AMEN1 | |
| SCHEMBL16954751 | 0.73 | LMNA (0.37) | ELANEKMT2AADRA2AADRA1AMEN1 | |
| SCHEMBL15463419 | 0.72 | ELANE (0.52) | ELANEALOX15CA2HTR1DHTR1B | |
| SCHEMBL809353 | 0.72 | ELANE (0.52) | ELANEALOX15CA2HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933296-B2 | Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors | ALTANA PHARMA B.V. (NL) | 2005-08-23 | — | — | US | disclosed |
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ALTANA PHARMA B.V. (NL) | 2003-10-16 | — | — | US | disclosed |
| EP-1296956-A1 | COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS | ALTANA Pharma AG (DE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001094319-A1 | COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS | ALTANA PHARMA AG (DE) | 2001-12-13 | — | — | WO | disclosed |
| US-5599966-A | SUITABLE FOR TREATMENT OF DISEASES OF RESPIRATORY PASSAGES | BYK NEDERLAND BV (NL) | 1997-02-04 | — | — | US | disclosed |
| WO-1994008945-A1 | SUBSTITUTED ETHANOLAMINE ESTERS | BYK NEDERLAND BV (NL) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ADRB1, ADRB2, ADRA1D | ELANE 1653/4885ALOX15 3901/4885CA2 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.